ReviewJournal of industrial microbiology & biotechnology2016
Natural product discovery: past, present, and future.
Review in Journal of industrial microbiology & biotechnology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 502 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
502 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Antimicrobial resistance crisis: could artificial intelligence be the solution?Military Medical Research · 2024Pooled it
- Actinomycetota-Derived Metabolites in Pancreatic Cancer: Chemical Diversity, Metabolic Vulnerability, and Translational Barriers.Current oncology reports · 2026Review
- Assessing Knowledge, Attitude, and Practices of Dentists on Antibiotic Use for Pediatric Dental Infections in Bangladesh: A Cross-Sectional Study.Health science reports · 2026Article
- Discovery and Biosynthetic Characterization of Darumycins Expand the Chemical Space of Sesterterpene Antibiotics.JACS Au · 2026Article
- Systematic Categorization and Functional Diversity of Secondary Metabolites from Bacillus spp.: A Review.Probiotics and antimicrobial proteins · 2026Review
- From antibiotic to chalkophore: the biology and evolution of SF2768 in Streptomyces.Essays in biochemistry · 2026Review
- When context matters: community and environmental context to elicit natural products.Essays in biochemistry · 2026Review
- Filamentous multiscale characterization of the cultivation of Actinomadura namibiensis pellets for model-based prediction of labyrinthopeptin A1 biosynthesis.Microbial cell factories · 2026Article
- Antimicrobial Trioxacarcin 1,2-Dihydroxyanthraquinones from the BacteriumBiomolecules · 2026Article
- Regulatory and metabolic control of microbial biosynthetic gene clusters.Communications biology · 2026Review
- DiscERN: an automated genome mining tool for the discovery of evolutionarily related natural products.Nature communications · 2026Article
- Article
- Bat skin microbiome and the association of ecoregion and bat species that impacted isolation of members with bioactivity against Pseudogymnoascus destructans.Animal microbiome · 2026Article
- Multiplexing antibiotic screening assay in droplet microfluidics.Scientific reports · 2026Article
- Natural Products Targeting Acetylation in Bladder Cancer: Mechanistic Basis, Therapeutic Potential, and Future Perspectives.Current issues in molecular biology · 2026Review
- One-step in vivo assembly of a 63 kb-long biosynthetic gene cluster via multiple recombination in Aspergillus oryzae.Applied microbiology and biotechnology · 2026Article
- Mutational basis of ceftazidime-borrelidin A collateral sensitivity in Escherichia coli.G3 (Bethesda, Md.) · 2026Article
- Multi-organ histological assessment of Agrococcus sp. RKDAS_1 reveals tissue-level biocompatibility in Oreochromis niloticus.Journal of molecular histology · 2026Review
- Tick-vectored mobilization of antibiotic resistance genes: transboundary dissemination across wildlife-livestock-vector-environment interfaces.NPJ biofilms and microbiomes · 2026Article
- Review
442 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microorganisms have provided abundant sources of natural products which have been developed as commercial products for human medicine, animal health, and plant crop protection. In the early years of natural product discovery from microorganisms (The Golden Age), new antibiotics were found with relative ease from low-throughput fermentation and whole cell screening methods. Later, molecular genetic and medicinal chemistry approaches were applied to modify and improve the activities of important chemical scaffolds, and more sophisticated screening methods were directed at target disease states. In the 1990s, the pharmaceutical industry moved to high-throughput screening of synthetic chemical libraries against many potential therapeutic targets, including new targets identified from the human genome sequencing project, largely to the exclusion of natural products, and discovery rates dropped dramatically. Nonetheless, natural products continued to provide key scaffolds for drug development. In the current millennium, it was discovered from genome sequencing that microbes with large genomes have the capacity to produce about ten times as many secondary metabolites as was previously recognized. Indeed, the most gifted actinomycetes have the capacity to produce around 30-50 secondary metabolites. With the precipitous drop in cost for genome sequencing, it is now feasible to sequence thousands of actinomycete genomes to identify the "biosynthetic dark matter" as sources for the discovery of new and novel secondary metabolites. Advances in bioinformatics, mass spectrometry, proteomics, transcriptomics, metabolomics and gene expression are driving the new field of microbial genome mining for applications in natural product discovery and development.
Indexed as
Identifiers
26739136What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.